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Abstract
To explore the variability in biosensor studies, 150 participants from 20 countries were given the
same protein samples and asked to determine kinetic rate constants for the interaction. We chose a
protein system that was amenable to analysis using different biosensor platforms as well as by
users of different expertise levels. The two proteins (a 50-kDa Fab and a 60-kDa glutathione S-
transferase [GST] antigen) form a relatively high-affinity complex, so participants needed to
optimize several experimental parameters, including ligand immobilization and regeneration
conditions as well as analyte concentrations and injection/dissociation times. Although most
participants collected binding responses that could be fit to yield kinetic parameters, the quality of
a few data sets could have been improved by optimizing the assay design. Once these outliers
were removed, the average reported affinity across the remaining panel of participants was 620
pM with a standard deviation of 980 pM. These results demonstrate that when this biosensor assay
was designed and executed appropriately, the reported rate constants were consistent, and
independent of which protein was immobilized and which biosensor was used.
Keywords
Biacore; Kinetics; Optical biosensor; Surface plasmon resonance
One of the hurdles we face as biosensor technology matures is in fact educating new users.
From our yearly reviews of the biosensor literature, it is clear that many users do not know
how to implement the technology properly [1], [2] and [3]. Therefore, over the past 7 years,
we have taken an active approach to educating users through a series of benchmark studies.
Typically, these studies involve sending the same samples to different users and asking them
to perform a detailed analysis of an interaction. Along with educating the participants on
how to properly execute an analysis, we gain valuable information about the reliability and
variability of biosensor-obtained results.
In past benchmark studies, we showed that the rate constants obtained using surface-based
biosensors and solution-based methods agree well [4], [5] and [6] and that when biosensor
users were provided with a detailed protocol, the variability in reported parameters was
approximately 20% [6], [7], [8] and [9]. This consistency, both between surface and solution
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methods and between users, holds true for biological systems that range in size from
antibody/antigen interactions [8] to small molecule/target interactions [4],[5], [6], [7] and [9]
and that range in kinetics from those that associate relatively slowly [8] to mass transport-
limited systems [4], [7] and [9].
The next step in establishing the biosensor’s reliability is to ask what the deviations in the
reported rate constants are when users design their own experiments and use a variety of
biosensor platforms. For this study, we provided aliquots of two binding partners (a 50-kDa
Fab and a 60-kDa glutathione S-transferase [GST]1-tagged Ag) to a pool of volunteers and
asked them each to determine the kinetics of the interaction. The participants were free to
explore different experimental parameters, including which partner to immobilize, covalent
coupling and/or capturing methods, and analyte conditions such as concentration range,
injection times, and flow rate.
As illustrated in Fig. 1, 150 scientists from 20 countries contributed to this study. The
participants, from industrial, government, and academic institutions, ranged both in
biosensor expertise and in biological focus. Fig. 1 also illustrates the variety of biosensors
used in this study. Although the experiment was most often performed using Biacore
platforms (Fig. 2A), instruments from nine other manufacturers were involved. The
instruments varied in their detection methods (from surface plasmon resonance [SPR]-based
detection to alternative optical and acoustic techniques), sampling throughput (from open
benchtop models to dedicated high-throughput screening platforms), flow cell design (from
multiple serial independent flow cell to single large-format flow cell of array platforms), and
surface chemistry (from plain gold to dextran-, alginate-, and poly(ethylene glycol)-coated
surfaces).
The participants designed their own experiments, fit the responses to obtain kinetic
parameters, and summarized their results. We evaluated how individuals approached the
task, and we identified mistakes in experimental design and data analysis that led to
inaccurate results. Overall, we were pleased to see that the quality of most of the biosensor
data was very high, and we are happy that enthusiastic participation in these benchmark
studies continues as the biosensor user community grows.
Materials and methods
Reagents
For the study, 50 µl of the two protein binding partners (Fab and GST–PcrV at 10 µM in
HBS-P [10 mM Hepes, 150 mM NaCl, and 0.005% Tween 20 at pH 7.4], prepared as
described in Ref. [10]) was distributed on dry ice to the participants. Each participant
provided all other materials required for the analysis.
Experiment instructions
Participants were asked to determine interaction kinetic and affinity parameters at 25 °C in
HBS-P supplemented with 0.1 mg/ml bovine serum albumin (BSA). They were told that the
binding partners were well behaved and stable.
Results
As the model system for this study, we chose a protein/protein interaction that could be
characterized using any of today’s commercially available affinity-based biosensors;
remained active under different immobilization, analysis, and regeneration conditions; and
was representative of the interactions typically studied by both novice and expert biosensor
users. The participants developed their own approaches to characterize this system; a
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number used more than one biosensor platform and/or surface, compared various
immobilization methods, and studied the interaction in both orientations.
Assay format
Participants used one (or more) of the five assay formats illustrated in Fig. 3. As indicated in
Fig. 2B most commonly used was the classic format, where the dissociation phase is
monitored for the same length of time for each analyte concentration (Fig. 3A). A more
efficient approach, the combination of short and long dissociation times (or short-‘n-long
[SNL] dissociation), collects more dissociation information for only one analyte
concentration (usually the highest concentration [Fig. 3B]). This approach works because
the decay in the signal of the highest analyte concentration provided enough information to
establish the dissociation rate constant (kd). Shortening the dissociation times of the lower
analyte concentrations decreases the time required for an experiment.
But both of the formats in Fig. 3A and B require regenerating the ligand surface after each
analyte injection. Identifying suitable regeneration conditions can be challenging in some
cases. The three alternative formats shown in Fig. 3C–E (one-shot kinetics, kinetic titration,
and ligand array) do not require a regeneration step. For example, with Bio-Rad’s one-shot
kinetics [11] or ForteBio’s dip-and-read approach [12], a user collects kinetic data for
several analyte concentrations across several target protein surfaces at one time. For kinetic
titration, several analyte concentrations are injected (usually in increasing order) across the
ligand surface in a single binding cycle [13]. In the ligand array format, analyte at one
concentration is flowed over a matrix of ligand spots within a single large flow cell [14].
These formats consume less reagent material and require minimal scouting and so can
decrease the time required for the experiment.
Ligand immobilization
Participants decided which binding partner to tether to the surface and which immobilization
chemistry to use. To choose the ligand, a number of participants performed preliminary
tests, including nonspecific binding and pH scouting tests. For example, injecting the Fab
and Ag across an unmodified flow cell surface revealed that neither protein bound
nonspecifically to the surface (Fig. 4A). Also, injections of the Fab and Ag diluted in weak
acid solutions (10 mM sodium acetate) indicated that both proteins preconcentrated well at
pH 4.5 (Fig. 4B). Based on these results, either protein could be immobilized. But nearly
two-thirds of the participants chose to tether the Ag to the surface (Fig. 2C), with many
noting that they made this choice to minimize complications that might arise from
dimerization of the GST-tagged Ag if it was used as the analyte.
For both Fab and Ag immobilization, most participants used standard amine coupling (Fig.
2C). Alternatively, some participants captured the ligand on antibody surfaces (the Ag and
Fab were captured by anti-GST and anti-Fab antibodies, respectively). A few participants
directly adsorbed one binding partner on a gold surface or minimally biotinylated it for
capture on a streptavidin surface.
Fig. 2D and E illustrate the range and number of ligand densities prepared by the
participants. For the most part, the ligands were immobilized at low densities to minimize
the potential effects of surface crowding, ligand aggregation, and mass transport (Fig. 2D).
In addition, nearly one-fourth of the participants immobilized the ligand at more than one
density to perform a more rigorous analysis (Fig. 2E).
Participants found a wide range of regeneration conditions suitable for this analysis.
Although most used an acidic solution (Fig. 2F), viable alternatives included dilute base,
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sodium dodecyl sulfate (SDS), guanidine, and a cocktail. Of course, for those using one of
the formats depicted in Fig. 3C–E, no surface regeneration was necessary.
Analyte parameters
When preparing the analyte samples, the participants needed to optimize several factors to
obtain reliable binding responses. For example, they needed to choose what flow rate to use,
what analyte concentrations to test, and how much association and dissociation data to
collect.
Aware that slow flow rates can contribute to mass transport effects, several participants
performed a preliminary flow rate test in which the analyte (at one concentration) was
injected at several flow rates across the ligand surface. Fig. 5 shows the results from flow
rate tests of Ag and Fab, each immobilized at two densities. In both panels, the analyte
binding responses at all flow rates overlaid, indicating that the interaction (in both
orientations) under these conditions was independent of mass transport. This allowed
participants to justifiably use lower flow rates (if they wished) so that they could consume
less sample per analyte injection or extend the analyte injection time. The pie chart in Fig.
2G illustrates the wide range of flow rates used in this experiment for the flow-based
systems. (In the ForteBio-based experiments, samples were not flowed. Instead, the ligand-
coated tips were dipped in the analyte-containing wells of a shake plate[12]. In IAsys, the
sample is stirred in a cuvette rather than flowed across a surface.)
Recognizing that high analyte concentrations can introduce artifacts (e.g., binding responses
can become contaminated by secondary interactions), the majority of participants used 100
nM (of either Fab or Ag) as the highest concentration (Fig. 2H). Except for some array
experiments, which were designed to test only one concentration (denoted as a 1-fold
dilution factor), the participants most often tested a 2- or 3-fold dilution series of the analyte,
although a few used up to a 10-fold dilution (Fig. 2I). A subset of participants did not use a
serial dilution series (indicated by the bars at the far right in Fig. 2I). In general, a 2- or 3-
fold dilution series is easy to set up, and it is much easier to visually interpret the data when
they are in a consistent dilution series.
The greatest variability in experimental design arose from the participants’ choices of how
long to collect association and dissociation phase data. Injection times ranged widely, from
25 s to 50 min, with 1 to 5 min being most common (Fig. 2J). Although all participants
collected dissociation data for at least 1 min, a 1-h dissociation phase was not unusual and a
few monitored the complex’s dissociation for up to 4 h (Fig. 2K).
Nearly two-thirds (65%) of participants tested at least one analyte concentration twice, with
most testing at least one concentration in duplicate or triplicate (Fig. 2L). Analyte replicates
demonstrated the reproducibility of the participants’ analyses; overlaid replicates confirmed
that both ligand and analyte were stable throughout the experiment and that the regeneration
condition was appropriate.
Binding responses
Fig. 6, Fig. 7 and Fig. 8 show all of the participants’ data sets, grouped by instrument used
and subgrouped by ligand and immobilization method. (It should be noted that the lettering
of the author list and the participant data sets are not related). Although most participants
tested the interaction on one surface, several Biacore users collected responses from three
ligand surfaces in standard Biacore platforms (e.g., Fig. 6A, P, DA, BC, and ZE) or up to
144 spots in the Flexchip analyses (Fig. 6DH and FH). Similarly, some Bio-Rad users took
advantage of the ProteOn XPR36’s ability to monitor six interactions in parallel (Fig. 7GH,
NH, and SH).
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Even with a brief glance at these figures, we see that overall the binding profiles are very
similar across the panel (regardless of which instrument was used and which binding partner
was tethered to the surface). In fact, all but 1 of the 259 data sets (Fig. 6HC) contained
interpretable responses. In addition, Fig. 6, Fig. 7 and Fig. 8 illustrate the range of the
participants’ experimental parameters, (e.g., assay format, immobilization densities, dilution
series) and, in some cases, the reproducibility of replicate analyses.
Data analysis
In the data sets returned by the participants (Fig. 6, Fig. 7 and Fig. 8), 94% included an
overlay of the data with the fit of an interaction model. A visual inspection of the plots
shows that most of the data sets fit well to the chosen model. The overwhelming majority of
participants fit their data using either a simple or mass transport-limited 1:1 model.
However, a few participants fit their data with models that were more complex than 1:1. For
example, a few data sets (e.g., Fig. 6MB and YC and Fig. 7TH) were fit using a drifting
baseline model. But the application of a drifting baseline model can provide misleading
results; in fact, all of the affinities obtained using this model were weaker than the average
(up to 30-fold). Alternatively, four participants used a heterogeneous or bivalent fitting
model (e.g., Fig. 6GA and KA), most likely to account for the slight complexity, which
arises from nonspecific binding, that was detected at their higher analyte concentrations.
Reported rate constants
Fig. 9A provides a visual summary of the kinetics reported by the participants. In this kd
versus association rate constant (ka) plot, the rate constants produce an expected Gaussian
distribution. We have labeled many of the outliers on this plot so that the reader can look at
the quality of data associated with these results. We highlighted five particularly egregious
outliers (shown as circles in Fig. 9A) that produced off rates that differed from the average
by 100-fold or more, a result of not observing decay in the dissociation phase, significant
baseline drift, or both. For example, two data sets displayed unusually slow off rates (Fig.
6UD and Fig. 7YH). In modeling these data, the fitting algorithms had difficulty in defining
the off rate because no decay in the dissociation phase was apparent (instead, upward drift is
obvious in Fig. 7YH). Conversely, downward drift is most likely the cause of the unusually
fast off rates reported for the data in Figs. 6CE and 8XI. From the data shown in Fig. 8XI,
we cannot confirm that the instrument was drifting prior to the analysis, but in our
experience we have found that initial drifting baselines are common in array biosensors and
that these systems require significant time to establish a stable baseline. Finally, the data set
in Fig. 8WI contains only association phase data. It is challenging to define the kd for a
slowly dissociating system without collecting some data points in the dissociation phase.
The remaining 253 data sets were included in our statistical analyses of the reported rate
constants. Therefore, the overall kinetics determined for this interaction were ka = (1.4 ±
1.3) × 105 M−1 s−1,kd = (6.1 ± 8.7) × 10−5 s−1, and equilibrium dissociation constant (KD) =
0.62 ± 0.98 nM. As illustrated by the number of data points that lie on the periphery of (or
beyond) the central cluster in Fig. 9A, omitting only five data points was a conservative
approach and, not surprisingly, produced large standard deviations in the overall averages.
In the figure, some of the peripheral data points are labeled according to the data set
assignments shown in Fig. 6. By examining the responses in these selected data sets, it is
apparent that the design and/or execution of many of these experiments could be optimized
(e.g., by extending the association phase and/or dissociation phase, testing lower analyte
concentrations, and eliminating instrument drift).
In Fig. 9A, the reported kinetics are also grouped by which binding partner was immobilized
on the surface. Overall, the parameters determined from the Ag and Fab surfaces overlay
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well and display a similar distribution range, thereby establishing that the kinetics were
independent of which binding partner was immobilized. This system, therefore, is an
example that refutes the skeptic’s argument that even for monomeric interactants the binding
constants depend on which molecule is immobilized. Instead, it demonstrates the utility,
flexibility, and reliability of affinity biosensors to resolve kinetic parameters when the
studies are done properly.
Fig. 9B and C shows the reported kinetic parameters grouped by how the ligand was
tethered to the sensor surface and assay format, respectively. These plots indicate that
similar rate constants were obtained regardless of whether the ligand was amine coupled,
captured (by antibody or streptavidin), or spotted (Fig. 9B). Likewise, the agreement
between groups of data points in Fig. 9C demonstrates that all five assay formats illustrated
in Fig. 3 produced similar results.
Fig. 10 shows the reported constants grouped by biosensor platform. Although we cannot
evaluate the reliability of instruments from which we obtained only one data set (i.e., GWC,
IAsys, Nanofilm, and Nomadics), the overlay of data sets from the other 14 platforms
demonstrates that the choice of platform did not inherently influence the reported rate
constants (Fig. 10A). To better identify the parameters obtained from specific platforms,
Fig. 10B and C show only the data from Biacore and other manufacturers, respectively. The
average rate constants obtained from each platform are listed in Table 1.
In Fig. 11, the reported constants are plotted against immobilization density. Even though
some participants prepared particularly high-density surfaces (up to 9000 resonance units
[RU]), the rate constants and affinities, for the most part, are randomly distributed about the
average (shown at the dotted lines) across the very wide range of immobilization densities.
Although at the highest densities (>2000 RU) the rate constants overall begin to deviate
from the average, the lack of an apparent trend in each panel of Fig. 11 confirms that mass
transport did not influence these interaction kinetics.
But the plots in Fig. 11 do not indicate how well the reported rate constants actually describe
the obtained binding responses. Typically, at high immobilization densities, the fit of a 1:1
interaction model can be suboptimal. Likewise, a simple interaction model tended to better
describe the responses collected from Ag surfaces compared with Fab surfaces. As several
participants noted, testing the GST-tagged Ag binding to Fab surfaces could introduce
avidity effects. This effect is apparent in the comparison of Fig. 7GH and SH; the model
overlays the responses in Fig. 7GH better than in Fig. 7SH even though the Ag surface
densities in the former are higher than the Fab surface densities in the latter. From these
studies overall, the best fits were obtained when participants tested the Fab binding to
relatively low-density Ag surfaces.
Discussion
Benchmark studies are an important tool to educate biosensor users and the overall scientific
community. Unlike previous studies, this time we did not provide a detailed protocol for the
participants to follow. Instead, they each selected an assay format and immobilization
method, performed preliminary binding tests and the full kinetic analysis, and submitted a
detailed report that described their experimental approach, challenges, and results.
Although the deviations in the overall rate constants are larger here than in previous
benchmark studies (due to the experimental flexibility that we gave the participants), we
were pleased by the quality of most of the returned data sets. Several features illustrate the
care that participants invested in these experiments. For example, many data sets include
replicate analyte injections that demonstrate the reproducibility of the analysis. Also, a
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number of participants tested the interaction in both orientations and found the rate constants
to be independent of which binding partner was chosen as the ligand. We were surprised to
find that so many participants successfully performed the both-orientation experiment given
that getting matching rate constants requires using particularly low-density Fab surfaces to
minimize bivalent binding by the GST–Ag analyte (looking at the data sets in detail revealed
that the best fits were obtained when the Fab in solution was tested against the GST–Ag
surface). Several participants compared the rate constants obtained when the ligand was
captured on or covalently coupled to the sensor surface and found that the two approaches
gave similar results. Although this similarity might not be universal, the criticism that
immobilization via amine coupling changes the inherent activity is not true for this pair of
binding partners. Finally, nearly all participants recognized the importance of showing their
binding data overlaid with the model fit. These figures provided valuable information about
the reliability of the reported rate constants.
Of course, not all was perfect. In some cases, the instrument performance and/or the choice
of experimental parameters could have been further optimized. For example, instrument drift
produced responses that did not resemble the data pool at large. When these responses were
fit to a drifting baseline model, the model overlays the data well but yielded erroneous rate
constants. It would have been better if these participants had eliminated the drift
experimentally rather than fitting the drifting baseline. Another significant problem was
collecting too little data. The analyte injection needed to be long enough to observe
curvature, and the dissociation phase needed to be monitored long enough to observe decay
in the responses. This curvature and decay allow a modeling algorithm to define the rate
constants well.
Overall, we found that the following set of conditions produces the most reliable responses
and rate constants for this type of interaction. Stabilize the biosensor fully by priming
extensively with buffer to ensure that the baseline does not drift. Prepare low-density (<100
RU) surfaces of the GST-tagged protein even though the system is not mass transport-
limited (this approach minimizes avidity and potential crowding effects). Inject the analyte
for a relatively long time (≥15 min). Collect wash phase data for at least 1 h to observe
significant dissociation of this stable complex. Test replicate analyte injections to evaluate
the stability of the binding partners and the suitability of the regeneration condition. Fit the
responses to a 1:1 interaction model.
This benchmark study has demonstrated that reliable rate constants are obtainable by
independent investigators using a range of biosensor technologies. We caution, however,
that to some extent the ability of this group to generate high-quality data is not reflective of
the average biosensor user’s skill level. These participants responded to a mass e-mail that
we sent to our contacts, who are often individuals with some connection to our group (e.g.,
through workshops, collaborations, and/or general interest) and would be considered well-
connected users. They also clearly have an interest in learning more about the biosensor
technology, as evidenced by their willingness to participate actively in these studies. We are
pleased to have such a large number of volunteers from around the world dedicate time and
effort to this project. It is educational for us, for them, and for the general scientific
community.
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Abbreviations used
GST glutathione S-transferase
SPR surface plasmon resonance
BSA bovine serum albumin
SNL short-‘n-long
kd dissociation rate constant
SDS sodium dodecyl sulfate
ka association rate constant
KD equilibrium dissociation constant
RU resonance units
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Fig. 1.
Locations of, and instruments used by, the study participants.
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Fig. 2.
Participants’ experimental parameters. (A) Instruments used, with Biacore platforms
indicated in red and other manufacturers’ platforms indicated in blue. (B) Assay formats,
with those requiring surface regeneration in red and other formats in blue. (C) Immobilized
binding partners and tethering methods, with Ag as the ligand in red and Fab as the ligand in
blue. (D) Immobilization densities for the Ag (red) and Fab (blue) from experiments
performed using Biacore and Bio-Rad platforms. (The other technologies report responses in
units other than resonance units [RU].) (E) Numbers of surfaces prepared. Analyses of two
or more surfaces are shown in shades of blue. (F) Regeneration conditions, with nonacidic
conditions shown in blue. (G) Flow rates used during analyte binding studies. (H) Highest
Rich et al. Page 13
Anal Biochem. Author manuscript; available in PMC 2013 October 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
analyte concentrations. (I) Dilution factors. (J) Lengths of analyte injection time. (For the
ForteBio experiments, this corresponds to the time that the ligand-immobilized tips were
immersed in analyte-containing wells.) (K) Lengths of time that the dissociation phase was
monitored (dissociation was not monitored in the IAsys experiment.) In panels H–K, red
bars represent parameters for Ag as the binding partner in solution and blue bars represent
Fab in solution. (L) Numbers of replicates when Ag (red) and Fab (blue) were the binding
partners in solution. (For interpretation of color mentioned in this figure the reader is
referred to the web version of the article.)
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Fig. 3.
Types of assay format used in the study. (A) Classic: several analyte concentrations flowed
serially across an immobilized ligand with a surface regeneration step between each
injection. (B) SNL (short-‘n-long) dissociation: several analyte concentrations with a
relatively short dissociation phase and one analyte concentration with a much longer
dissociation phase flowed serially across an immobilized ligand with a regeneration step
between each injection. (C) One-shot: several analyte concentrations flowed in parallel
across a ligand surface without surface regeneration. (D) Kinetic titration: several analyte
concentrations flowed serially over a ligand surface without surface regeneration. (E)
Ligand array: a single analyte concentration flowed simultaneously across multiple
immobilized ligand spots of different densities without surface regeneration. In this nine-
spot array example, the ligand was spotted three times at three concentrations. RU,
resonance units.
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Fig. 4.
Preimmobilization tests of Fab (left) and Ag (right). (A) Nonspecific binding test: the
responses from injections of a buffer blank and 100 nM protein across an unmodified sensor
chip are overlaid. (B) pH scouting: 100 nM protein was injected at different pH levels to
identify the optimal pH for ligand preconcentration. RU, resonance units.
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Fig. 5.
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Fig. 6.
Data sets submitted by participants using Biacore instruments. Participants A–D used
Biacore A100, participants E to KA used Biacore T100, participants LA to SA used Biacore
S51, participants TA to QD used Biacore 3000, participants RD to PG used Biacore 2000,
participants QG and RG used Biacore 1000, participants SG and TG used Biacore X100,
participants UG to BH used Biacore X, and participants CH to FH used Biacore Flexchip.
The choice of ligand immobilized (Ag or Fab) is indicated on the left. The method of
tethering the ligand to the surface (immobilization, capture, or spotting) is indicated on the
right. RU, resonance units.
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Fig. 7.
Data sets submitted by participants using the Bio-Rad ProteOn XPR36 instrument. The
choice of ligand immobilized (Ag or Fab) is indicated on the left. The method of tethering
the ligand to the surface (immobilization or capture) is indicated on the right. RU, resonance
units.
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Fig. 8.
Data sets submitted by participants using other manufacturers’ instruments. The choice of
ligand immobilized (Ag or Fab) is indicated on the left. The method of tethering the ligand
to the surface (immobilization, capture, or spotting) is indicated on the right. RU, resonance
units.
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Fig. 9.
kd versus ka plots of the kinetic parameters determined by the participants. Dashed diagonals
depict isoaffinity lines. Circles indicate the five data sets omitted from the statistical
analysis. (A) Analyses of Ag surfaces are shown in red, and Fab surfaces are shown in blue.
Data sets peripheral to the central cluster are noted by participant assignment. (B) Analyses
grouped by ligand tethering method. (C) Analyses grouped by assay design. In each panel,
the average and standard deviation for each group are listed below the plot. (For
interpretation of color mentioned in this figure the reader is referred to the web version of
the article.)
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Fig. 10.
kd versus ka plots grouped by biosensor platform. (A) Kinetics obtained from all instrument
types. (B) Kinetics obtained from the various Biacore platforms. (C) Kinetics obtained from
instruments produced by other manufacturers. Dashed diagonals depict isoaffinity lines. The
average and standard deviation for each group are listed in Table 1.
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Fig. 11.
Kinetic parameters plotted against immobilization density. Ag surfaces are indicated in red,
and Fab surfaces are indicated in blue. In each panel, the dashed line indicates the average
determined value. RU, resonance units. (For interpretation of color mentioned in this figure
the reader is referred to the web version of the article.)
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